Correction

Publication
Article
Cardiology Review® OnlineNovember 2008
Volume 25
Issue 11

Cardiology Review

In the October 2008 issue of , we incorrectly stated in our Product Spotlight section that “Boston Scientific received approval in July 2008 for their Xience™ V Everolimus-Eluting Coronary Stent for the treatment of coronary artery disease.” It should have said that Abbott Vascular received this approval and will market the Xience V. Abbott supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS™ Everolimus-Eluting Coronary Stent System. We regret the mistake.

For more on stents, please look for our Stent Round Table in December.

Related Videos
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
© 2024 MJH Life Sciences

All rights reserved.